André F Ciruelos EM, Rubovsky M, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial. ESMO 2018, abstract LBA3_PR.
Alectinib versus crizotinib bij ALK-positief NSCLC
jun 2017 | Longoncologie